Descripción de la empresa
PRF Technologies Ltd. operates as a clinical stage specialty pharmaceutical company dedicated to the reformulation of established therapeutics, with a specific focus on providing extended periods of post-surgical pain relief within the Israeli market. The firm develops PRF-110, a viscous clear oil-based solution designed to be instilled directly into surgical sites to manage pain effectively. This business falls squarely within the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry, positioning it as a developer of niche medicinal products rather than a broad-spectrum manufacturer. The company's scale is currently defined by a market capitalization of $1.59M and reported annual revenue of $17,000, with no employee count data available in the provided records. These valuation and revenue figures indicate that PRF Technologies Ltd. functions as a micro-cap entity with a very limited operational footprint relative to large-scale pharmaceutical corporations, suggesting a high-risk profile typical of early-stage biotechnology firms where capital is heavily invested in research and development before commercialization.
Salud financiera
The company reported a revenue of $17,000 over the trailing twelve months, yet simultaneously recorded a net income of $-4,838,000 and an EBITDA of $-4,348,000, revealing a profound structural gap where costs far exceed earnings. This massive disparity between nominal revenue and significant negative net income highlights an aggressive cost structure driven by heavy investment in clinical trials, regulatory filings, and R&D expenses that have not yet generated sufficient commercial returns. The free cash flow stands at $-2,449,250, indicating that the company is burning through its liquidity reserves to fund its operations and development pipeline, which severely limits its immediate financial flexibility. Despite these operational deficits, the balance sheet holds $4.14M in cash against a negligible debt load of $21,000, resulting in a debt-to-equity ratio of 0.23 that suggests a conservative leverage position rather than a leveraged one. The current ratio is recorded at 1.78, which indicates a healthy liquidity position where current assets significantly exceed current liabilities, providing a buffer against short-term obligations. However, the return on equity is a negative -90.4% and the return on assets is -38.7%, metrics that reveal that management has not yet been effective in generating profit from the capital invested in the business. The gross margin is 0.0%, the operating margin is a negative -16,200.0%, and the profit margin is 0.0%, figures that collectively demonstrate the company is in a pre-profitability phase where revenue does not cover the substantial costs of goods sold or operational overhead.
Evaluación de valoración
The trailing P/E ratio is not applicable (N/A) due to negative earnings, while the forward P/E is listed as -0.17, a metric that implies the market is pricing in a period of continued negative earnings or a restructuring of the cost base before profitability is achieved. The price-to-book ratio stands at 0.20, indicating that the stock is trading at a significant discount to its book value, which often suggests the market perceives high risk or undervalued assets within the company's portfolio. The price-to-sales ratio is an extremely high 93.28, a metric that suggests the market is valuing the company almost entirely on its potential future growth rather than current cash flows or historical performance. The enterprise value to EBITDA ratio is 0.39, which, combined with the negative EBITDA, reflects a valuation model based on projected turnaround potential rather than current operational cash generation. The stock's trading range over the past year spans from a 52-week low of $1.80 to a 52-week high of $17.95, meaning the current price sits somewhere within this wide band, exhibiting significant volatility common in micro-cap biotech stocks. The beta value is not applicable (N/A), precluding a direct comparison of price volatility relative to the broader market index, though the wide trading range between $1.80 and $17.95 inherently signals high price sensitivity to market sentiment and sector-specific developments.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both not applicable (N/A), as the company has not yet established a consistent historical track record of growth rates required to calculate these annualized percentages. In the absence of positive earnings growth, it is impossible to determine if earnings are growing faster than revenue, but the negative net income implies that the company is not yet scaling profitably alongside its top-line activities. As the company does not pay a dividend, with a dividend yield of N/A and a payout ratio of 0.0%, it follows a capital allocation strategy where all available earnings are reinvested into research, development, and operational expansion rather than being distributed to shareholders. This lack of dividend income and the absence of measurable growth rates summarize an overall profile characterized by a speculative growth phase where income generation is secondary to the pursuit of commercializing the PRF-110 therapeutic solution.